VA
ONC

Vident Advisory’s BeOne Medicines Ltd ONC Stock Holding History

Vident Advisory’s Portfolio ONC Stock Details ONC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$738K Buy
2,486
+434
+21% +$140K 0.01% 1030
2025
Q4 		$623K Buy
2,052
+347
+20% +$114K 0.01% 1036
2025
Q3 		$581K Buy
+1,705
New +$518K 0.01% 1115
2024
Q3 		– Sell
-1,567
Closed -$224K – 1580
2024
Q2 		$224K Buy
+1,567
New +$242K 0.01% 1242
2024
Q1 		– Sell
-1,409
Closed -$254K – 1447
2023
Q4 		$254K Sell
1,409
-33
-2% -$5.97K 0.01% 1088
2023
Q3 		$259K Buy
+1,442
New +$285K 0.01% 992

Other funds holding ONC

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vident Advisory's ONC Position: Q1 2026 in Review

Vident Advisory increased its BeOne Medicines Ltd (ONC) stake by 21% in Q1 2026, buying an estimated $140K and bringing the position to 2,486 shares worth $738K. The position accounts for 0.01% of the portfolio, ranked #1030.

Vident Advisory first reported a position in ONC in Q3 2023 and has held it in 6 quarters since. 281 funds tracked by Wall St. Rank hold ONC as of Q1 2026.

  • Vident Advisory held 2,486 shares of BeOne Medicines Ltd worth $738K as of Q1 2026.
  • Vident Advisory bought 434 BeOne Medicines Ltd shares in Q1 2026, an estimated $140K.
  • BeOne Medicines Ltd made up 0.01% of Vident Advisory's portfolio in Q1 2026, its #1030 holding.
  • Vident Advisory first reported a position in BeOne Medicines Ltd in Q3 2023 and has held it in 6 quarters since.
  • 281 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q1 2026.

Based on Vident Advisory's 13F filing for Q1 2026, filed 15 May 2026.